Continuous Bioprocessing Market Summary

The global continuous bioprocessing market size was estimated at USD 349.3 million in 2024 and is projected to reach USD 911.4 million by 2030, growing at a significant compound annual growth rate (CAGR) of 18.63% from 2025 to 2030. This impressive growth is primarily driven by the increasing demand for cost-efficient, scalable, and flexible biopharmaceutical production solutions, especially for the manufacturing of monoclonal antibodies (mAbs), vaccines, and advanced cell and gene therapies.

Continuous bioprocessing offers distinct advantages over traditional batch processing methods by supporting process intensification—achieved through automation, real-time process analytics, and the use of single-use technologies. These advancements significantly enhance overall productivity, reduce production times, and minimize operational costs. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are encouraging the shift toward continuous manufacturing due to its potential to improve process consistency, enable better quality control, and accelerate time-to-market for critical biologics.

Key Market Trends & Insights

• Based on product type, the consumables and reagents segment led the global market in 2024, accounting for the largest revenue share. This dominance is fueled by the widespread adoption of single-use technologies (SUTs), improved cell culture media formulations, and the increasing need for high-quality, contamination-free reagents that ensure uninterrupted and sterile continuous bioproduction environments.
• By application, the monoclonal antibodies segment captured the largest revenue share of 29.98% in 2024. The demand for monoclonal antibodies continues to grow due to their effectiveness in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. Continuous bioprocessing is enabling biopharma companies to meet this rising demand with scalable, consistent, and cost-efficient production capabilities.
• The vaccines segment is projected to register the fastest CAGR from 2025 to 2030. This rapid growth is attributed to the global push for rapid and scalable vaccine production post the COVID-19 pandemic. Continuous manufacturing offers the agility and efficiency required for future pandemic preparedness and global immunization initiatives.
• Among end-users, pharmaceutical and biotechnology companies accounted for the largest market share of 48.43% in 2024. The shift from traditional batch methods to continuous production is being embraced to meet growing demands for biologics such as mAbs, biosimilars, gene therapies, and next-generation vaccines. These companies are adopting automated perfusion systems and integrated bioprocessing platforms to boost operational efficiency, reduce cost, and ensure product quality and scalability.
• North America dominated the global continuous bioprocessing market in 2024, with the largest revenue share of 37.46%. This is supported by substantial investments in biopharmaceutical research and development, an advanced biomanufacturing ecosystem, and favorable regulatory support, particularly from the FDA, which has been actively promoting continuous manufacturing models.
• In the U.S., the continuous bioprocessing industry is gaining traction due to the presence of major biopharma companies, extensive R&D pipelines, and growing demand for advanced therapeutic modalities like mAbs and gene therapies. The country’s regulatory ecosystem also encourages innovation through the adoption of automated, real-time monitoring systems and perfusion-based bioreactors.
• The Asia Pacific region is witnessing rapid growth in the continuous bioprocessing market, driven by increasing biopharma investments, expansion of biosimilar production, and the emergence of biomanufacturing hubs in nations such as China, India, South Korea, and Japan. Governments and private sectors are actively investing in infrastructure and technology to bolster local biologics production.
• Europe represents a mature market characterized by robust regulatory frameworks, strong biotech R&D spending, and the presence of leading global players such as Sanofi, Roche, and Novartis. The European Medicines Agency (EMA) supports innovation in manufacturing practices, including continuous bioprocessing, resulting in wider adoption of technologies such as real-time analytics and continuous chromatography.
• The Latin American market is steadily emerging, fueled by growing interest in domestic biologics production, increasing demand for biosimilars, and supportive government initiatives aimed at boosting local manufacturing capabilities. Countries like Brazil, Argentina, and Mexico are attracting international collaborations and investments to enhance their biomanufacturing capacities through continuous processing technologies.

Order a free sample PDF of the Continuous Bioprocessing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 349.3 Million
• 2030 Projected Market Size: USD 911.4 Million
• CAGR (2025-2030): 18.63%
• North America: Largest market in 2024

Key Companies & Market Share Insights

Companies' key strategies for maintaining their market presence include mergers, acquisitions, and licensing deals for R&D activities. Moreover, companies are expanding their global presence, forming strategic partnerships, and investing in automation and AI-driven bioprocessing solutions to enhance efficiency and scalability in biologics manufacturing.

Key Players

• Danaher
• Sartorius AG
• Thermo Fisher Scientific Inc.
• WuXi Biologics
• Ginkgo Bioworks
• Merck KGaA
• GE Healthcare
• Repligen Corporation
• Asahi Kasei Bioprocess America, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global continuous bioprocessing market is experiencing strong growth, supported by the rising demand for scalable, cost-effective biologic production. Innovations in single-use technologies, automation, and real-time monitoring are reshaping traditional biomanufacturing paradigms. Key therapeutic areas such as monoclonal antibodies and vaccines continue to drive adoption. Regions like North America and Asia Pacific lead due to favorable investments and infrastructure, while Europe and Latin America offer significant opportunities through regulatory support and expanding production capacities. As the need for personalized medicines and next-generation biologics grows, continuous bioprocessing will play an increasingly vital role in shaping the future of global biopharmaceutical manufacturing.